Skip to main content

Boehringer Ingelheim Announces Acquisition of the Remaining Shares in Boehringer Ingelheim Shionogi Vetmedica (BISV)

Pressmeddelande   •   Dec 03, 2004 13:15 CET

Nippon Boehringer Ingelheim today announced that it acquired the remaining third of the shares held by Shionogi of Boehringer Ingelheim Shionogi Vetmedica Co. Ltd. (BISV). The new name of the company will be announced in due course.

BISV was founded in April 2002 and was originally set up as a joint venture between Shionogi & Co. Ltd and Nippon Boehringer Ingelheim Co. Ltd for marketing, sale and development of products for the Japanese animal health market providing solutions in the swine, cattle and poultry segments.
Future plans for the Japanese animal health market include to further strengthening its position in swine vaccines and to expand its position in the companion animal segment.

The acquisition of the Shionogi shares further underlines the commitment of Boehringer Ingelheim Animal Health to strengthen the global animal health position.

Shionogi & Co, Ltd
Shionogi & Co., Ltd. is a listed company that is headquartered in Osaka, Japan. It is a major research-driven Japanese pharmaceutical manufacturer. The company’s primary businesses are research and development, manufacturing, marketing, and import and export sales of pharmaceuticals and diagnostics.

Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 152 affiliates in 45 countries and more than 34,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2003, Boehringer Ingelheim posted net sales of 7.4 billion euro while spending more than one fifth of net sales in its largest business segment Prescription Medicines on research and development.

The animal health business is conducted in 20 countries including USA, Canada, Germany, France, UK, Italy, Spain, Mexico, the Nordic countries and Japan. Since 1954, Boehringer Ingelheim Animal Health is contributing to an adequate supply of safe, nutritious food and is promoting the emotional and physical benefits arising from the human-animal bond.

Contact:
Boehringer Ingelheim GmbH
Julia Meyer-Kleinmann
55216 Ingelheim am Rhein
GERMANY
Phone: +49/6132/77 82 71
Fax: +49/6132/77 66 01